+

WO2000062790A3 - Traitement de troubles d'ordre medical par un recepteur de facteur de necrose tumorale soluble - Google Patents

Traitement de troubles d'ordre medical par un recepteur de facteur de necrose tumorale soluble Download PDF

Info

Publication number
WO2000062790A3
WO2000062790A3 PCT/US2000/010565 US0010565W WO0062790A3 WO 2000062790 A3 WO2000062790 A3 WO 2000062790A3 US 0010565 W US0010565 W US 0010565W WO 0062790 A3 WO0062790 A3 WO 0062790A3
Authority
WO
WIPO (PCT)
Prior art keywords
medical disorders
necrosis factor
tumor necrosis
factor receptor
soluble tumor
Prior art date
Application number
PCT/US2000/010565
Other languages
English (en)
Other versions
WO2000062790A8 (fr
WO2000062790A2 (fr
Inventor
Barbara K Finck
Original Assignee
Immunex Corp
Barbara K Finck
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp, Barbara K Finck filed Critical Immunex Corp
Priority to CA2366785A priority Critical patent/CA2366785C/fr
Priority to AU43632/00A priority patent/AU4363200A/en
Priority to EP00923525A priority patent/EP1171148A2/fr
Publication of WO2000062790A2 publication Critical patent/WO2000062790A2/fr
Priority to US09/778,403 priority patent/US20010021380A1/en
Priority to EP01918237A priority patent/EP1259252A2/fr
Priority to AU2001245336A priority patent/AU2001245336A1/en
Priority to CA002416250A priority patent/CA2416250A1/fr
Priority to PCT/US2001/006037 priority patent/WO2001062272A2/fr
Publication of WO2000062790A3 publication Critical patent/WO2000062790A3/fr
Publication of WO2000062790A8 publication Critical patent/WO2000062790A8/fr
Priority to US10/314,618 priority patent/US20030148955A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a trait à des méthodes de traitement de troubles d'ordre médical caractérisés par de niveaux élevés ou par une expression anormale de facteur de nécrose tumorale alpha par l'administration d'un antagoniste du facteur de nécrose tumorale alpha, par exemple un récepteur du facteur de nécrose tumorale recombinant (TNFR:Fc)
PCT/US2000/010565 1999-04-19 2000-04-19 Traitement de troubles d'ordre medical par un recepteur de facteur de necrose tumorale soluble WO2000062790A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA2366785A CA2366785C (fr) 1999-04-19 2000-04-19 Traitement de troubles d'ordre medical par un recepteur de facteur de necrose tumorale soluble
AU43632/00A AU4363200A (en) 1999-04-19 2000-04-19 Soluble tumor necrosis factor receptor treatment of medical desorders
EP00923525A EP1171148A2 (fr) 1999-04-19 2000-04-19 Traitement de troubles d'ordre medical par un recepteur de facteur de necrose tumorale soluble
US09/778,403 US20010021380A1 (en) 1999-04-19 2001-02-07 Soluble tumor necrosis factor receptor treatment of medical disorders
PCT/US2001/006037 WO2001062272A2 (fr) 2000-02-25 2001-02-22 Recepteur soluble du facteur de necrose tumorale utilise dans le traitement de certaines affections medicales
EP01918237A EP1259252A2 (fr) 2000-02-25 2001-02-22 Recepteur soluble du facteur de necrose tumorale et il-4 inhibiteur utilise dans le traitement de certaines affections medicales
AU2001245336A AU2001245336A1 (en) 2000-02-25 2001-02-22 Soluble tumor necrosis factor receptor treatment of medical disorders
CA002416250A CA2416250A1 (fr) 2000-02-25 2001-02-22 Recepteur soluble du facteur de necrose tumorale utilise dans le traitement de certaines affections medicales
US10/314,618 US20030148955A1 (en) 1999-04-19 2002-12-09 Soluble tumor necrosis factor receptor treatment of medical disorders

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US13007499P 1999-04-19 1999-04-19
US60/130,074 1999-04-19
US13432099P 1999-05-14 1999-05-14
US60/134,320 1999-05-14
US14395999P 1999-07-15 1999-07-15
US60/143,959 1999-07-15
US14823499P 1999-08-11 1999-08-11
US60/148,234 1999-08-11
US37382899A 1999-08-13 1999-08-13
US09/373,828 1999-08-13
US16467699P 1999-11-10 1999-11-10
US60/164,676 1999-11-10
US18486400P 2000-02-25 2000-02-25
US60/184,864 2000-02-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US60235100A Continuation-In-Part 1999-04-19 2000-06-23

Publications (3)

Publication Number Publication Date
WO2000062790A2 WO2000062790A2 (fr) 2000-10-26
WO2000062790A3 true WO2000062790A3 (fr) 2001-07-12
WO2000062790A8 WO2000062790A8 (fr) 2001-08-02

Family

ID=27568861

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/010565 WO2000062790A2 (fr) 1999-04-19 2000-04-19 Traitement de troubles d'ordre medical par un recepteur de facteur de necrose tumorale soluble

Country Status (4)

Country Link
EP (1) EP1171148A2 (fr)
AU (1) AU4363200A (fr)
CA (1) CA2366785C (fr)
WO (1) WO2000062790A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517963B2 (en) 1989-08-07 2009-04-14 Arana Therapeutics Limited Tumour necrosis factor binding ligands
US7605233B2 (en) 1989-08-07 2009-10-20 Arana Therapeutics Limited Tumour necrosis factor binding ligands

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
EP2270149B1 (fr) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
BR0108193A (pt) * 2000-02-10 2003-02-25 Wyeth Corp Processo para tratamento ou inibição de dano celular ou morte celular
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2002058717A2 (fr) * 2000-10-18 2002-08-01 Immunex Corporation Methodes de traitement de la polyarthrite rhumatoide a l'aide d'antagonistes de l'il-17
CN1612750B (zh) 2001-05-24 2012-10-31 津莫吉尼蒂克斯公司 Taci-免疫球蛋白融合蛋白质
WO2003009864A1 (fr) * 2001-07-23 2003-02-06 Genset S.A. Agonistes et antagonistes de disomet pour le traitement de troubles metaboliques
GB0128138D0 (en) * 2001-11-23 2002-01-16 King S College London Pharmaceutical use
EP1946776B1 (fr) 2002-02-27 2017-01-18 Immunex Corporation Composition tnfr-fc stabilisée comportant une arginine
DK1478394T3 (da) * 2002-02-27 2008-10-13 Immunex Corp Stabiliseret TNFR-Fc formulation med arginin
AU2004279742A1 (en) * 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
TWI399383B (zh) 2005-05-16 2013-06-21 Abbott Biotech Ltd ＴＮＦα抑制劑於治療侵蝕型多發性關節炎之用途
EA012801B1 (ru) 2005-06-14 2009-12-30 Эмджен Инк. Самобуферирующиеся композиции белков
EP1922080A2 (fr) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Procedes destines au traitement des malignites des lymphocytes b au moyen d'une molecule de fusion taci-ig
EP1922079A2 (fr) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Procedes pour le traitement et la prevention de proliferation cellulaire anormale par le biais de molecules de fusion taci
WO2007082542A1 (fr) * 2006-01-17 2007-07-26 Astion Pharma A/S Préparations comprenant de l’oxaprozine et un analogue de vitamine d3 et leur emploi dans la fabrication d'un médicament pour le traitement du psoriasis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
WO2007121538A1 (fr) * 2006-04-26 2007-11-01 Plasma Ventures Pty Ltd Produit sanguin anti-inflammatoire et procede d'utilisation
AR060935A1 (es) 2006-05-15 2008-07-23 Ares Trading Sa Metodos para tratar enfermedades autoinmunes utilizando una molecula de fusion taci- ig
KR101673654B1 (ko) 2011-04-20 2016-11-07 산도즈 아게 융합 단백질 TNFR:Fc의 안정한 제약 액체 제제
MX358137B (es) * 2011-07-01 2018-08-06 Biogen Idec Inc Composiciones del polipéptido de fusión tnfr: fc exentas de arginina y métodos de uso.
TW201325607A (zh) 2011-10-18 2013-07-01 Coherus Biosciences Inc 用胺基酸穩定化之依那西普調配物
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
CA2878508A1 (fr) * 2012-07-09 2014-01-16 Coherus Biosciences, Inc. Formulations d'etanercept presentant une reduction marquee en particules invisibles a l'oeil nu
LT2895188T (lt) 2012-09-11 2018-04-10 Coherus Biosciences, Inc. Aukšto grynumo ir geros išeigos teisingos struktūros etanerceptas
US20160017020A1 (en) 2013-03-06 2016-01-21 Protalix Ltd. Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
EP3268042B1 (fr) 2015-03-13 2024-11-27 Samsung Bioepis Co., Ltd. Composition contenant un polypeptide anti-tnf-alpha et utilisation
US20180311199A1 (en) * 2016-01-12 2018-11-01 Lawrence Chan Combination treatment for inflammatory diseases
JP6884858B2 (ja) 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024463A2 (fr) * 1996-12-06 1998-06-11 Amgen Inc. Therapie combinatoire utilisant une proteine de liaison du facteur de necrose tumorale (tnf) dans le traitement de maladies induites par le tnf
EP0869179A1 (fr) * 1997-04-02 1998-10-07 Smithkline Beecham Corporation Récepteur en rapport avec la nécrose des tumeurs, TR7

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024463A2 (fr) * 1996-12-06 1998-06-11 Amgen Inc. Therapie combinatoire utilisant une proteine de liaison du facteur de necrose tumorale (tnf) dans le traitement de maladies induites par le tnf
EP0869179A1 (fr) * 1997-04-02 1998-10-07 Smithkline Beecham Corporation Récepteur en rapport avec la nécrose des tumeurs, TR7

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DE RIE M A ET AL: "Low-dose narrow-band UVB phototherapy combined with topical therapy is effective in psoriasis and doses not inhibit systemic T-cell activation.", DERMATOLOGY (BASEL), vol. 196, no. 4, 1998, pages 412 - 417, XP000960479, ISSN: 1018-8665 *
ETTHEDAI P ET AL: "Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions.", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 96, no. 1, 1994, pages 146 - 151, XP000960434, ISSN: 0009-9104 *
HOEHLER THOMAS ET AL: "A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis.", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 109, no. 4, 1997, pages 562 - 565, XP000960470, ISSN: 0022-202X *
MEASE PHILIP ET AL: "Enbrel(R) (Etanercept) in patients with psoriatic arthritis and psoriasis.", ARTHRITIS & RHEUMATISM, vol. 42, no. 9 SUPPL., 1999, 63rd Annual Scientific Meeting of the American College of Rheumatology and the 34th Annual Scientific Meeting of the Association of Rheumatology Health Professionals;Boston, Massachusetts, USA; Novemb, pages S377, XP000960436, ISSN: 0004-3591 *
MEASE PHILIP J ET AL: "Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial.", LANCET (NORTH AMERICAN EDITION), vol. 356, no. 9227, 29 July 2000 (2000-07-29), pages 385 - 390, XP002152293, ISSN: 0099-5355 *
NICKOLOFF BRIAN J: "Pathogenesis and immunointervention strategies for psoriasis (IBC's inflammatory skin disorders) (Washington, DC, USA;September 17-18, 1998; National Psoriasis Foundation).", MOLECULAR MEDICINE TODAY, vol. 4, no. 12, December 1998 (1998-12-01), pages 512 - 513, XP000960433, ISSN: 1357-4310 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517963B2 (en) 1989-08-07 2009-04-14 Arana Therapeutics Limited Tumour necrosis factor binding ligands
US7528237B2 (en) 1989-08-07 2009-05-05 Arana Therapeutics Limited Tumour necrosis factor binding ligands
US7544782B2 (en) 1989-08-07 2009-06-09 Arana Therapeutics Limited Tumour necrosis factor binding ligands
US7553641B2 (en) 1989-08-07 2009-06-30 Arana Therapeutics Limited Tumour necrosis factor binding ligands
US7605233B2 (en) 1989-08-07 2009-10-20 Arana Therapeutics Limited Tumour necrosis factor binding ligands

Also Published As

Publication number Publication date
CA2366785C (fr) 2012-02-07
EP1171148A2 (fr) 2002-01-16
AU4363200A (en) 2000-11-02
CA2366785A1 (fr) 2000-10-26
WO2000062790A8 (fr) 2001-08-02
WO2000062790A2 (fr) 2000-10-26

Similar Documents

Publication Publication Date Title
WO2000062790A3 (fr) Traitement de troubles d'ordre medical par un recepteur de facteur de necrose tumorale soluble
WO2001062272A3 (fr) Recepteur soluble du facteur de necrose tumorale utilise dans le traitement de certaines affections medicales
WO2002032374A3 (fr) Methodes de traitement de troubles induits par l'il-18
WO2001087328A3 (fr) Inhibiteurs d"interleukine 1 dans le traitement de maladies
WO2003014309A3 (fr) Recepteurs de l'interleukine-1 dans le traitement de maladies
WO2000064441A3 (fr) Medicament
IL146482A (en) Tek antagonists
WO2004009784A3 (fr) Nouveaux inhibiteurs de kinases
WO2001001748A3 (fr) Composés se liant à her2
WO2005048935A3 (fr) Methodes pour moduler l'immunite
WO2002022153A3 (fr) Procede permettant de traiter l'inflammation
WO2003013535A3 (fr) Moyens et methodes de traitement ameliore du cancer fondes sur mdr1
WO2004054514A3 (fr) Indazolylpyrrolotriazines c-6 modifiees
WO2004043341A3 (fr) Traitement pour choc hémorragique
WO2003042172A3 (fr) Indazolylpyrrolotriazines modifiees en c-5
IL145068A0 (en) The use of glycine betaine to prepare a pharmaceutical composition
WO2004064836A3 (fr) Traitement de maladies a l'aide d'agonistes totaux du recepteur nicotinique de l'acetycholine (achr) alpha-7
WO2003015713A3 (fr) Traitement de tumeurs gliales avec des antagonistes du glutamate
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO2002020768A3 (fr) Peptides de caveoline et leur utilisation comme agents therapeutiques
WO2002094196A3 (fr) Methode de traitement de cancers associes a des niveaux de her-2 eleves
WO2004055513A3 (fr) Utilisation d'antagonistes de cd137 pour le traitement de tumeurs
WO2002096420A3 (fr) Procede de traitement d'accidents nerveux entraines par une operation
BG104092A (en) Cd154 blockade therapy for the treatment of protein inhibition syndrome
WO2000051582A3 (fr) Procedes de traitement de l'apnee et de troubles de l'apnee a l'aide de r(+) ondansetron optiquement pur

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE AND DELETE THE PUBLISHED FIGURE

ENP Entry into the national phase

Ref document number: 2366785

Country of ref document: CA

Ref country code: CA

Ref document number: 2366785

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000923525

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 515435

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 2000923525

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000923525

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载